Home » Novartis Stops Breast Cancer Study Early Following Positive Results
Novartis Stops Breast Cancer Study Early Following Positive Results
Novartis halted a Phase 3 trial early for a breast cancer candidate after meeting its primary endpoint of clinically meaningful improvement.
The candidate treatment, in combination with letrozole, was found to significantly extend progression-free survival when compared to letrozole alone, the Swiss drug giant says.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May